The Efficacy of Botulinum Toxin Type A in the Treatment of Allodynic-Type Neuropathic Pain in People With Spinal Cord Injury or Multiple Sclerosis

Trial Profile

The Efficacy of Botulinum Toxin Type A in the Treatment of Allodynic-Type Neuropathic Pain in People With Spinal Cord Injury or Multiple Sclerosis

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2015

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Oct 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 09 Apr 2015 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov record.
    • 09 Apr 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top